Show simple item record

dc.contributor.authorDesai, Darashen_US
dc.date.accessioned2015-08-04T15:36:09Z
dc.date.available2015-08-04T15:36:09Z
dc.date.issued2014
dc.date.submitted2014
dc.identifier.other
dc.identifier.urihttps://hdl.handle.net/2144/12087
dc.descriptionThesis (Ph.D.)--Boston Universityen_US
dc.description.abstractCounterfeit and substandard medicines are a grave public health concern that comprises a $75B black market and claims over 100,000 lives every year. The World Health Organization estimates that 10-50% of medicines in countries around the world are adulterated, and their presence imposes serious financial and economic burdens while also contributing to the rise of drug-resistant pathogens. Although a plethora of technologies are available for field-based quality screening, none reliably quantify active pharmaceutical ingredient (API) content or kinetic release from a dissolving tablet. The United States Pharmacopeia, a global leader in medicines standards for over 150 years, indicates that these quality measures are vitally important yet remain outside of the reach ofexisting screening tools. The current field standard relies on thin layer chromatography to only provide qualitative results that make it difficult to discern between tablets that contain 80% and 100% API. Meanwhile, international standards set the threshold for substandard medicines at 90%. This clear lack of appropriately quantitative and field- ready analytical tools poses a serious problem for national and international policymakers who are plagued with wildly variable information that prevents focused and deliberate action against the spread ofthese medications. This work presents an alternative analytical technique that can specifically and accurately quantify drug API content and kinetic release. PharmaChk provides an orthogonal approach to existing technologies using a portable, inexpensive, and easy-to-use platform. We demonstrate that aptamers can provide a simple and effective way to target a wide range of APis, while maintaining high quantitative precision and accuracy. A microfluidic, flow-through system is employed to obtain valuable drug quality information using a single step procedure. Through our research, we demonstrate the development of the PharmaChk platform from the proof-of-concept stage to beta prototyping and field-testing. By providing a portable, robust, and quantitative approach to medicines testing, PharmaChk can enable the collection of important drug quality information throughout pharmaceutical supply chains and ultimately save the lives of millions that are not afforded safe and essential medicines.en_US
dc.language.isoen_US
dc.publisherBoston Universityen_US
dc.titlePharmachk: robust device for counterfeit and substandard medicines screening on developing regionsen_US
dc.typeThesis/Dissertationen_US
etd.degree.nameDoctor of Philosophyen_US
etd.degree.leveldoctoralen_US
etd.degree.disciplineBiomedical Engineeringen_US
etd.degree.grantorBoston Universityen_US


This item appears in the following Collection(s)

Show simple item record